Drug Profile
Research programme: secondary hyperparathyroidism therapy - LEO Pharma
Alternative Names: KH 1722; Secondary hyperparathyroidism therapy research programme - LEO PharmaLatest Information Update: 26 Mar 2010
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperparathyroidism
Most Recent Events
- 26 Oct 2004 Preclinical trials in Hyperparathyroidism in Denmark (unspecified route)